背景:关于叶酸摄入量和生物标志物与死亡风险之间关系的现有证据存在争议。
目的:先前的队列研究检查了叶酸摄入量和生物标志物与全因风险的关系,心血管疾病(CVD),和癌症相关死亡率通过系统评价和荟萃分析。
方法:对PubMed进行了系统搜索,Scopus,和截至2023年7月的ISIWebofScience数据库。
方法:前瞻性队列研究检查叶酸生物标志物的相关性(血清,等离子体,红细胞)和具有全因风险的摄入,CVD-,并考虑了与癌症相关的死亡率.随机效应模型被应用于结合研究特定的风险估计。通过1阶段加权混合效应荟萃分析评估剂量-反应关系。
方法:共有25个队列,423304名参与者,36558全因,12662CVT-,纳入2426例癌症相关死亡病例.叶酸生物标志物的最高水平与全因死亡风险之间没有观察到显著关联(风险比[HR],0.91;95%CI,0.77-1.06;n=17;I2=89.4%;P<.001),CVD相关死亡风险(HR,0.97;95%CI,0.87-1.06;n=11;I2=0.0%;P=.57),和癌症相关的死亡风险(HR,0.85;95%CI,0.69-1.05;n=6;I2=57.8%;P=.04)与最低相比。此外,每增加10nmol/L与全因死亡风险降低12%略有相关,但与CVD和癌症相关死亡风险无关.发现膳食叶酸的最高摄入量与最低摄入量之间存在显着负相关,和所有原因的风险(HR,0.87;95%CI,0.78-0.96;n=3;I2=63.6%;P=.06)和CVD(HR,0.77;95%CI,0.57-0.93;n=4;I2=80.2%;P=0.002)死亡率。
结论:这项荟萃分析显示,膳食叶酸摄入量与全因死亡率和CVD死亡率之间存在显著的负相关关系。在叶酸生物标志物的情况下没有发现这样的关联。需要进一步的前瞻性研究来证实这些发现。
背景:PROSPERO注册号。CRD42023401700。
BACKGROUND: Existing evidence on the relation between
folate intake and biomarkers with mortality risk is controversial.
OBJECTIVE: Previous cohort studies were examined regarding
folate intake and biomarkers in relation to risk of all-cause, cardiovascular disease- (CVD), and cancer-related mortality through a systematic review and meta-analysis.
METHODS: A systematic search was performed of the PubMed, Scopus, and ISI Web of Science databases up to July 2023.
METHODS: Prospective cohort studies examining the association of
folate biomarkers (in serum, plasma, red blood cells) and intake with risk of all-cause, CVD-, and cancer-related mortality were considered. A random-effects model was applied to combine study-specific risk estimates. Dose-response relations were assessed by 1-stage weighted mixed-effects meta-analysis.
METHODS: A total of 25 cohorts with 423 304 participants, 36 558 all-cause, 12 662 CVD-, and 2426 cancer-related deaths were included. No significant association was observed between the highest levels of
folate biomarkers and all-cause mortality risk (hazard ratio [HR], 0.91; 95% CI, 0.77-1.06; n = 17; I2 = 89.4%; P < .001), CVD-related mortality risk (HR, 0.97; 95% CI, 0.87-1.06; n = 11; I2 = 0.0%; P = .57), and cancer-related mortality risk (HR, 0.85; 95% CI, 0.69-1.05; n = 6; I2 = 57.8%; P = .04) compared with the lowest. Furthermore, each 10 nmol/L increase was marginally related to a 12% reduced all-cause mortality risk but not to CVD- and cancer-related mortality risk. A significant inverse association was found between highest intake of dietary folate and the lowest, and risk of all-cause (HR, 0.87; 95% CI, 0.78-0.96; n = 3; I2 = 63.6%; P = .06) and CVD (HR, 0.77; 95% CI, 0.57-0.93; n = 4; I2 = 80.2%; P = .002) mortality.
CONCLUSIONS: This meta-analysis revealed a significant inverse relation between dietary folate intake and risk of all-cause and CVD mortality. Such an association was not found in the case of
folate biomarkers. Further prospective studies are warranted to confirm these findings.
BACKGROUND: PROSPERO registration no. CRD42023401700.